Skip to main content Accessibility help
×
Home

Delayed Onset of Neuropsychiatric Effects Associated with Montelukast

  • Fintan Byrne (a1), Bolarinwa Oluwole (a2), Vanessa Whyte (a3), Sabina Fahy (a4) and Delia McGuinness (a5)...

Abstract

Montelukast (a leukotriene receptor antagonist) is a commonly prescribed medication used in the management of asthma in both children and adults. It has been associated with a possible increased risk of various neuropsychiatric events in post-marketing analyses of clinical trial data and surveillance studies. When establishing a link between a medication and side effects, it is usual to establish and enquire whether there is a chronological relationship between the commencement of the medication and the onset of the symptoms.

We report a case where a number of unusual neuropsychiatric events were reported several years after commencement of montelukast in a young boy who may have a genetic predisposition and a likely psychological trigger. There was complete resolution of these symptoms upon the withdrawal of montelukast.

Copyright

Corresponding author

*Correspondence Email: fintanbyrne@gmail.com

References

Hide All
1. Global Strategy for Asthma Management and Prevention 2009 (Update)
2. Full Drug Prescribing information, MERCK & CO., INC. available at www.singulair.com/montelukast_sodium/hcp/asthma/prescribing-information.jsp accessed 17/09/10
3. Canadian Drug Bank available at http://www.drugbank.ca/drugs/DB00471 accessed 17/09/10
4.Cohen, S, Taitz, J, and Jaffé, A. Paediatric prescribing of asthma drugs in the UK: are we sticking to the guideline? Arch Dis Child 2007; 92:847849.
5.Wallerstedt, SMet al.Montelukast and psychiatric disorders in children. Pharmacoepidemiol Drug Saf. 2009 09;18(9):858–64
6.Leukotriene inhibitors: montelukast (marketed as Singulair), zafirlukast (marketed as Accolate), and zileuton (marketed as Zyflo and Zyflo CR). Healthcare Professional Sheet, Washington (DC): US Food and Drug Administration; 2009.
7.Philip, G, Hustad, C, Noonan, G, Malice, M-P, Ezekowitz, A, Reiss, TF, et al.Reports of suicidality in clinical trials of montelukast. J Allergy Clin Immunol 2009;124:691–6
8.Philip, G, Hustad, CM, Malice, M-P, Noonan, G, Ezekowitz, A, Reiss, TF, et al.Analysis of behaviour-related adverse experiences in clinical trials of montelukast. J Allergy Clin Immunol 2009;124:699706
9.Kelsay, K. Assessing risk: Data from montelukast clinical trials. J Allergy Clin Immunol 2009;124:697–8
10.Goodwin, R, Eaton, W. Asthma, suicidal ideation, and suicide attempts: findings from the Baltimore epidemiological catchment area follow-up. Am J Public Health 2005; 95:717–22.
11.McQuaid, E, Kopel, S, Nassau, J. Behavioral adjustment in children with asthma. J Dev Behav Pediatr 2001; 22:430–9.
12.Skillman, K, Stumpf, J. Montelukast-induced anxiety in two pediatric patients. Pharmacotherapy 2011; 31:524.
13.Naranjo, CA, Busto, U, Sellers, EM, Sandor, P, Ruiz, I, et al.A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239245.

Keywords

Delayed Onset of Neuropsychiatric Effects Associated with Montelukast

  • Fintan Byrne (a1), Bolarinwa Oluwole (a2), Vanessa Whyte (a3), Sabina Fahy (a4) and Delia McGuinness (a5)...

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed